PL2054050T3 - Leczenie zaburzeń chrząstki z zastosowaniem FGF-18 - Google Patents

Leczenie zaburzeń chrząstki z zastosowaniem FGF-18

Info

Publication number
PL2054050T3
PL2054050T3 PL07802876T PL07802876T PL2054050T3 PL 2054050 T3 PL2054050 T3 PL 2054050T3 PL 07802876 T PL07802876 T PL 07802876T PL 07802876 T PL07802876 T PL 07802876T PL 2054050 T3 PL2054050 T3 PL 2054050T3
Authority
PL
Poland
Prior art keywords
fgf
treatment
cartilage disorders
cartilage
disorders
Prior art date
Application number
PL07802876T
Other languages
English (en)
Inventor
Alberto Gimona
Christoph H Ladel
Baur Elmar Vom
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of PL2054050T3 publication Critical patent/PL2054050T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL07802876T 2006-08-25 2007-08-24 Leczenie zaburzeń chrząstki z zastosowaniem FGF-18 PL2054050T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06119557 2006-08-25
US84060006P 2006-08-28 2006-08-28
PCT/EP2007/058830 WO2008023063A2 (en) 2006-08-25 2007-08-24 Treatment of cartilage disorders with fgf-18
EP07802876A EP2054050B1 (en) 2006-08-25 2007-08-24 Treatment of cartilage disorders with fgf-18

Publications (1)

Publication Number Publication Date
PL2054050T3 true PL2054050T3 (pl) 2013-01-31

Family

ID=38984134

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07802876T PL2054050T3 (pl) 2006-08-25 2007-08-24 Leczenie zaburzeń chrząstki z zastosowaniem FGF-18

Country Status (14)

Country Link
US (1) US8207115B2 (pl)
EP (1) EP2054050B1 (pl)
JP (2) JP5815206B2 (pl)
KR (1) KR101419961B1 (pl)
AR (1) AR062522A1 (pl)
AU (1) AU2007287510B2 (pl)
CA (1) CA2658511C (pl)
CY (1) CY1113136T1 (pl)
EA (1) EA015644B1 (pl)
HR (1) HRP20120643T1 (pl)
IL (1) IL197169A (pl)
MX (1) MX2009002063A (pl)
PL (1) PL2054050T3 (pl)
WO (1) WO2008023063A2 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012038953A2 (en) 2010-09-21 2012-03-29 Hepacore Ltd. Fgf-18 truncated variants having increased receptor specificity and uses thereof
WO2012140650A2 (en) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
US9421245B2 (en) * 2012-06-25 2016-08-23 The Brigham And Women's Hospital, Inc. Targeted therapeutics
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
PL2880181T3 (pl) * 2012-08-06 2019-03-29 Merck Patent Gmbh Biomarkery prognostyczne w zaburzeniach chrząstki
EP2880179B1 (en) 2012-08-06 2017-12-13 Merck Patent GmbH Genetic markers for predicting responsiveness to fgf-18 compound
NZ721332A (en) * 2013-12-24 2022-07-01 Ares Trading Sa Fgf-18 formulation in xyloglucan gels
HRP20181570T1 (hr) * 2014-02-20 2018-11-30 Merck Patent Gmbh Režim doziranja spoja fgf-18
KR102437057B1 (ko) * 2014-02-20 2022-08-26 메르크 파텐트 게엠베하 이식편 이식 및 조직 공학 절차에 있어서의 ｆｇｆ－１８
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
CA2971315C (en) 2015-01-29 2023-02-14 Ares Trading S.A. Immunoassays for high positively charged proteins
EP4137147A3 (en) * 2015-03-03 2023-04-05 Radius Health, Inc. Uses of abaloparatide in reducing fracture risk
MX384605B (es) 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
US11020454B2 (en) 2015-07-15 2021-06-01 Prosit Sole Biotechnology (Beijing) Co. Ltd Fusion polypeptides and methods of use
CA2994638A1 (en) * 2015-08-13 2017-02-16 Merck Patent Gmbh Combination composition comprising fgf-18 compound
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
CN107338218B (zh) * 2017-07-28 2020-11-24 中国人民解放军总医院第一附属医院 一种诱导脂肪干细胞向软骨细胞分化的诱导分化培养基和方法
KR20200054300A (ko) * 2017-09-21 2020-05-19 메르크 파텐트 게엠베하 Fgf-18 모이어티를 포함하는 융합 단백질
RS63292B1 (sr) 2017-09-29 2022-06-30 Merck Patent Gmbh Inflamatorni biomarkeri za predviđanje responsivnosti na jedinjenje fgf-18
LT3687558T (lt) 2017-09-29 2022-06-27 Merck Patent Gmbh Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
WO2020104833A1 (en) * 2018-11-19 2020-05-28 4P-Pharma Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
JP7671249B2 (ja) * 2019-02-08 2025-05-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 変形性関節症が急速に進行するリスクがある患者の治療
US12441745B2 (en) 2019-02-12 2025-10-14 Radius Pharmaceuticals, Inc. Processes and compounds
CN109836487B (zh) * 2019-03-01 2022-06-17 重庆派金生物科技有限公司 一种人成纤维细胞生长因子18及其可溶性重组表达方法、制备方法、制剂和应用
CN117721115A (zh) * 2022-09-06 2024-03-19 深圳瑞吉生物科技有限公司 用于治疗骨关节炎的mRNA及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0881908B1 (en) * 1994-03-08 2004-06-16 Osteosa Inc. Use of fibroblast growth factors to stimulate bone growth
US20050043234A1 (en) * 1996-10-16 2005-02-24 Deisher Theresa A. Novel FGF homologs
JPH11332570A (ja) * 1998-05-27 1999-12-07 Shionogi & Co Ltd 新規な線維芽細胞成長因子及びそれをコードする遺伝子
US7432049B2 (en) * 2001-02-28 2008-10-07 Chondrogene Limited Compositions and methods relating to osteoarthritis
ATE539157T1 (de) * 1999-12-02 2012-01-15 Zymogenetics Inc Methoden welche auf zellen zielen, die die fibroblasten wachtumsfaktor-rezeptoren-3 oder -2 exprimieren
EP1551426B1 (en) * 2002-10-07 2014-06-25 ZymoGenetics, Inc. Methods of administering fgf18
WO2006014444A1 (en) * 2004-07-06 2006-02-09 Zymogenetics, Inc. Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use
DK1828239T3 (da) * 2004-12-10 2011-12-19 Zymogenetics Inc FGF18-produktion i prokaryote værter

Also Published As

Publication number Publication date
JP5815206B2 (ja) 2015-11-17
EA200970224A1 (ru) 2009-08-28
IL197169A0 (en) 2009-12-24
US20100016223A1 (en) 2010-01-21
KR101419961B1 (ko) 2014-07-30
EP2054050A2 (en) 2009-05-06
EP2054050B1 (en) 2012-08-08
EA015644B1 (ru) 2011-10-31
US8207115B2 (en) 2012-06-26
WO2008023063A3 (en) 2008-05-02
MX2009002063A (es) 2009-03-06
AU2007287510A1 (en) 2008-02-28
AR062522A1 (es) 2008-11-12
KR20090051100A (ko) 2009-05-20
AU2007287510B2 (en) 2012-08-30
JP2014088429A (ja) 2014-05-15
CA2658511A1 (en) 2008-02-28
WO2008023063A2 (en) 2008-02-28
CA2658511C (en) 2019-02-19
JP2010501531A (ja) 2010-01-21
HRP20120643T1 (hr) 2012-08-31
IL197169A (en) 2013-08-29
CY1113136T1 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
ZA200900426B (en) Treatment of cartilage disorders with FGF-18
IL197169A0 (en) Use of fgf-18 in the manufacture of a medicament for treatment of cartilage disorders
ZA200900734B (en) Combination treatment for metabolic disorders
IL194189A0 (en) Combination treatment of metabolic disorders
IL230335A (en) A drug used to treat cartilage disease
IL185052A0 (en) Treatment of bone disorders
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
GB0703909D0 (en) Treatment of anxiety disorders
IL198488A0 (en) Treatment of pervasive developmental disorders
GB0624874D0 (en) Treatment
GB0909297D0 (en) Composition for the treatment of skin conditions
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
GB0619500D0 (en) Treatment of fibrosis
GB0723100D0 (en) Treatment of HFnEF
GB0607952D0 (en) Novel treatment
GB0604460D0 (en) Treatment
GB0623740D0 (en) Treatment of disease
ZA200902765B (en) Treatment of pulp
GB0602857D0 (en) The treatment of sialorrhoea
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
GB0625602D0 (en) Treatment of sialorrhoea
GB0618705D0 (en) Treatment of joint disorders
GB0619218D0 (en) Treatment of conformational disorders
GB0602855D0 (en) The Treatment Of Sialorrhoea
GB0602858D0 (en) The treatment of sialorrhoea